TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Migration of prosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative hepatocellular damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in intensity of constipation symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total radioactivity pharmacokinetics in whole blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity in the excreta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Hetrombopag in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of early neonatal death or neonatal encephalopathy
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of Major Adverse Events through 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving ≥ 30% Reduction in Mean Plasma iPTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants Achieving ≥ 30% Reduction in Mean Plasma Intact Parathyroid Hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dose proportionality of setanaxib tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-drug interactions of setanaxib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of safety after multiple oral administration
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Proximal Plaque Index (MPPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in depressive symptom
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Numeric Pain Rating scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck disability Index (NDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neck Proprioception test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck muscles endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in rhythmic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in early and intermediate-stage AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MDS UPDRS III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meaningful change in drug regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterisation of synovial tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Characterisation of synovial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: worsening of heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Daily pain scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean Change in Pediatric Quality of Life Inventory 4.0 (PedsQL) Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Continuous 6-month Abstinence from Smoking
Endpoint domain: Mortality/survival
Primary endpoint: Structural basis for bilateral brain interactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GLP-1 levels after a standard meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline score of The 12-item Health Survey Short Form (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain assessed by Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Thickness of the stabilizer muscles' belly
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Recommended Phase II dose of Ixabepilone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ∆sCD40L Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: disease-specific health-related quality of life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Concentration of uremic components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visualization of normal dural venous sinuses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patency of dural venous sinuses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Normal variations of dural venous sinuses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of metabolic control of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Daily dose of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Study Treatment Discontinuations Due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Intent to Vaccinate Adolescent Child
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immediate Memory Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delayed Memory Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Responders Rate at Week 6 (Pain While Moving)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory (cognitive side effects)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to reorientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in infiltrate thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cancer recurrence in 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Latency to relapse
Endpoint domain: Mortality/survival
Primary endpoint: Change in free fatty acids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in insulin blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemical Markers for Mitochondrial Biogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food Security
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception Barriers
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mortality or Multisystem Organ Failure Events
Endpoint domain: Mortality/survival
Primary endpoint: Neurologic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulmonary Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of new Covid infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mental Time Travel Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Client engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of New T1-weighted Gadolinium (Gd)-Enhancing Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of delivery < 34 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Develop Delayed Cerebral Vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful Insertion of Ablation Antenna
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to relapse (TTR)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Complete Response or Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Preservation of endogenous insulin secretion/beta-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline-adjusted forced expiratory volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: knee torque-angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of antirheumatic treatment escalations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: distribution of physical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placental Expulsion Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mortality at D28
Endpoint domain: Mortality/survival
Primary endpoint: Rate detection of FGR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of people with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Test of Adolescent Social Skills (TASSK)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Composite Patient Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cardiac Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and duration of colds and flu attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Freedom from death
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Citrulline levels in plasma or dried blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Complete Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes of uterine fibroids (maximal fibroids)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of Epithelialization of wound in %
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of color, contour and distortion of wound in total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of redness, presence of bleeding, granulation tissue, epithelialization and suppuration in %
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ADAMTS-13 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: von Willebrand factor antigen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: platelet-monocyte aggregates levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Therapeutic Efficacy of Darvadstrocel-Clinical
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic Efficacy of Darvadstrocel-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Total Radioactive Dose Excreted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of choline in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Internalizing problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time from groin puncture to clot contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Connor-Davidson's Resilience Scale (CDRISC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recommended dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-procedural IMR of PCI target vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Access time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effectiveness of Social Marketing Intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in overground walking endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0last
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With One or More Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration-time Curve of MK-2206 From Time 0 to 48 Hours (AUC0-48hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RA inflammatory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TG plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: therapeutical efficacy on pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Color Change for Urine Test for Measuring Cotinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiorespiratory function assessed by peak oxygen consumption (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Did Not Require Concomitant PRO to Complete MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum Diabetes screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Talazoparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Elimination Half-Life (t1/2) of Talazoparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual incidence of PI
Endpoint domain: Mortality/survival
Primary endpoint: Clearance of S-ketorolac and R+ Ketorolac in 2-6 Month Old Infants Following Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of S- and R+ Ketorolac in 2-6 Month Old Infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of S- and R+ Ketorolac in 6-18 Month Old Infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration-time curve (AUC) for Tafenoquine X
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroresponse Rates to All Antigens Contained in PR5I Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pulse Wave
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of the diagnosis of interstitial syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: All-cause death and/or rehospitalisation for cardiovascular causes
Endpoint domain: Mortality/survival
Primary endpoint: All-cause death and/or major stroke
Endpoint domain: Mortality/survival
Primary endpoint: Improvement/change in walking capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Total Restless Leg Syndrome Rating Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with differential causes of bronchiectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subject improvement based on investigator assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: COVID-19-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Invasive local failure at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Presence of septic arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Non-reassuring Fetal Heart Rate Tracings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall length of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: moisturizing of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: greasing of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: pH level of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Exercise group attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Exercise group persistence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Exercise group compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Exercise attitude
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in facial hirsutism by hair count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frontal EEG asymmetry indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objective Opiate Withdrawal Scale (OOWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in adhesion formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intention to engage in safe sex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Full-dose Donor Chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to SBRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Major Bleeding Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Major Thrombo-embolic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Velocity time index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective response rate observed in patients in the dose expansion portion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH Toolbox Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Fasting Plasma Glucose (FPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Times to reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intrahepatic triglycerides (IHTG) content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cardiovascular risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fatiguability of the diaphragm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of patients with infliximab failure
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of high-risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in cognition at 2 years
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in dementia severity at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quality of life at 2 years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC0-72 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of histologically confirmed breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Detection of specialized columnar epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Direct and indirect costs of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Radiographic bone width changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of febrile RTI-episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: longest diameter of renal angiomyolipomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: toxicity graded by National Cancer Institute's Common Terminology Criteria for Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: standardized patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in knee functional improvement by WOMAC index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes